India Globalization Capital Inc (IGC) - Total Liabilities
Based on the latest financial reports, India Globalization Capital Inc (IGC) has total liabilities worth $1.65 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore investment intensity of India Globalization Capital Inc to see how much of total assets are deployed in long-term investments.
India Globalization Capital Inc - Total Liabilities Trend (2006–2025)
This chart illustrates how India Globalization Capital Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see IGC total asset value.
India Globalization Capital Inc Competitors by Total Liabilities
The table below lists competitors of India Globalization Capital Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Sc Engineering
KO:023960
|
Korea | ₩77.98 Billion |
|
Cobalt Blue Holdings Limited
F:COH
|
Germany | €6.76 Million |
|
Gurktaler AG ST
VI:GAGS
|
Austria | €568.00K |
|
Duxton Farms Ltd
AU:DBF
|
Australia | AU$123.41 Million |
|
Geomega Resources Inc
V:GMA
|
Canada | CA$5.97 Million |
|
FN REPUBLIC Co. Ltd
KQ:064090
|
Korea | ₩3.75 Billion |
|
Nordic Mining ASA
OL:NOM
|
Norway | Nkr2.31 Billion |
|
Safari World PLC
BK:SAFARI
|
Thailand | ฿6.88 Billion |
Liability Composition Analysis (2006–2025)
This chart breaks down India Globalization Capital Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See net asset quality index of India Globalization Capital Inc to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.32 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.73 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.20 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.17 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how India Globalization Capital Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for India Globalization Capital Inc (2006–2025)
The table below shows the annual total liabilities of India Globalization Capital Inc from 2006 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | $2.42 Million | -6.35% |
| 2024-03-31 | $2.58 Million | +13.85% |
| 2023-03-31 | $2.27 Million | -22.94% |
| 2022-03-31 | $2.94 Million | -3.98% |
| 2021-03-31 | $3.06 Million | +25.21% |
| 2020-03-31 | $2.45 Million | +174.02% |
| 2019-03-31 | $893.00K | -67.97% |
| 2018-03-31 | $2.79 Million | -29.12% |
| 2017-03-31 | $3.93 Million | -19.90% |
| 2016-03-31 | $4.91 Million | -12.01% |
| 2015-03-31 | $5.58 Million | +55.52% |
| 2014-03-31 | $3.59 Million | -16.11% |
| 2013-03-31 | $4.28 Million | -54.70% |
| 2012-03-31 | $9.44 Million | -13.11% |
| 2011-03-31 | $10.87 Million | +17.94% |
| 2010-03-31 | $9.22 Million | -34.05% |
| 2009-03-31 | $13.97 Million | -47.77% |
| 2008-03-31 | $26.75 Million | +50.62% |
| 2007-03-31 | $17.76 Million | +12.72% |
| 2006-03-31 | $15.76 Million | -- |
About India Globalization Capital Inc
IGC Pharma, Inc., a clinical stage pharmaceutical company, develops treatments for Alzheimer's disease in the United States and Colombia. The company's lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's. Its pre-clinical stage product candidate includes TGR-63, IGC-M3, and LMP to treat Alzheimer's disease; IGC-1C for the treatm… Read more